GalNAc Ligand Stability and Targetability via Linker Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing targeting ligands containing N-acetylgalactosamine for liver-specific delivery of siRNA lack stability, targetability, and efficiency.
Innovation Solution
A novel targeting ligand containing N-acetylgalactosamine with a conjugated group shown in Formula (X′) is developed, which includes specific bonding configurations and protective groups to enhance stability and targetability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prior art targeting ligands containing GalNAc are used, then liver-specific delivery is achieved, but stability and targetability are insufficient
Solution Approach 1:
The patent applies composite materials by combining GalNAc with specific linkers (L1-L4), spacers (L, L'), and protective groups to create a composite ligand structure. This composite approach enhances stability through multiple functional components working together: the GalNAc provides targetability, the linkers provide structural integrity, and the protective groups enhance stability against degradation, thereby resolving the contradiction between reliability and ease of manufacture.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical parameters of the ligand structure, including different linker compositions (L1-L4 with varying lengths and chemical properties), spacer configurations (L and L' with different bond types), and protective group selections. These parameter optimizations enhance stability and targetability while maintaining synthetic feasibility, addressing the technical contradiction.
2Reliability
If prior art targeting ligands containing GalNAc are used, then liver-specific delivery is achieved, but targetability is insufficient
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the ligand structure: the GalNAc moiety is positioned to maximize ASGPR binding affinity, while the linkers (L1-L4) and spacers (L, L') are designed with specific local chemical properties to enhance targetability. The protective groups are strategically placed to prevent off-target effects. This localized optimization of different ligand regions enhances targetability without requiring complete structural redesign.
Solution Approach 2:
The patent employs segmentation by dividing the ligand into distinct functional segments: the GalNAc targeting moiety, the linkers (L1-L4), the spacers (L, L'), and the protective groups. This segmentation allows each component to be independently optimized for its specific function while maintaining overall structural coherence, thereby enhancing targetability without excessive complexity.
3Reliability
If GalNAc is coupled to siRNA, then liver targeted delivery is achieved, but stability is insufficient
Solution Approach 1:
The patent applies the intermediary principle by introducing linkers (L1-L4) and spacers (L, L') as intermediary components between the GalNAc and the siRNA. These intermediaries serve multiple functions: they provide structural stability to the conjugate, prevent direct interactions that could lead to degradation, and maintain the spatial arrangement necessary for both stability and functionality. This intermediary approach resolves the contradiction between stability and structural complexity.
Solution Approach 2:
The patent employs beforehand cushioning by incorporating protective groups that prevent degradation of the GalNAc-siRNA conjugate before it reaches its target. These protective groups act as a cushion against premature degradation by nucleases and other biological factors, ensuring the conjugate remains stable during circulation and delivery, thereby resolving the stability issue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel ligand achieves improved stability, targetability, and liver-specific delivery of siRNA, leading to enhanced therapeutic efficacy.
Implementation Method 1
N-acetylgalactosamine (GalNAc) can specifically bind to an asialoglycoprotein receptor (ASGPR) on surfaces of hepatocytes
Data Source
AI summary
Provided in the present invention is a ligand containing N-acetylgalactosamine, wherein the ligand contains a conjugated group as represented by formula (X′) and a nucleic acid molecule containing the targeting ligand.